CClinicalTrials.gg
RecruitingNCT07440303Updated Feb 27, 2026

Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT

An interventional study of Starmatrix collagen membrane and Autogenous gingival graft in Lack of Keratinized Gingiva and Mucogingival Deformity - Insufficient Keratinized Tissue, sponsored by Harvard Medical School (HMS and HSDM). Recruiting at 1 site in United States. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Harvard Medical School (HMS and HSDM) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2025, registered Feb 2026).
  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This split-mouth randomized controlled clinical trial will test whether a ready-to-use collagen membrane (Star Matrix) can widen the protective band of gum tissue (keratinized gingiva) as effectively as the standard free gingival graft harvested from the palate.

Central question Can Star Matrix provide the same or better gain in keratinized tissue width-with less patient discomfort and chair-time-than an autogenous graft?

Primary objectives

Compare the 6-month increase in keratinized tissue width between Star Matrix and autogenous graft sites.

Assess patient-reported pain and morbidity associated with each treatment.

Secondary objectives

Measure operative time, early healing scores, esthetic outcomes, and (optional) histologic quality of the regenerated tissue.

Methods Twelve adults with ≤ 2 mm keratinized tissue on contralateral lower-jaw teeth will be enrolled. Each participant receives Star Matrix on one side and a conventional free gingival graft on the other. Follow-up visits at 2, 4, 8, 12 and 24 weeks include clinical measurements, standardized photographs, and a 7-day postoperative pain diary. An optional 2 mm punch biopsy at 6 months is analyzed microscopically.

Read the detailed description

Healthy gums include a "band" of firm, pink tissue (keratinized gingiva) that helps people brush comfortably and protects the area where the tooth meets the bone. Studies suggest that when this band is narrower than about 2 mm, plaque control becomes harder and the risk of recession rises; in one maintenance study, nearly one-fifth of such sites lost further tissue over time.

Since the 1960s the standard way to widen this band has been a free gingival graft-moving a strip of the patient's own palatal tissue to the thin area. The technique works, but it also creates a second surgical wound, offers only a limited amount of donor tissue, causes notable postoperative pain, and the graft can look or feel different from nearby gum.

Researchers have explored substitutes such as preserved sclera, freeze-dried skin, and acellular dermal matrix, yet none has matched the predictability of a patient-derived graft. For example, acellular dermal matrix shrank by about 71 percent and often healed as scar-like tissue with inflammatory reactions.

Star Matrix is a new cross-linked collagen membrane made from highly purified porcine type I collagen. It combines a smooth outer coating that shields the wound with a porous inner layer that welcomes cell ingrowth and is placed porous side down to encourage the patient's own cells to replace it over time. Because it is supplied sterile and ready-to-use, Star Matrix eliminates the donor-site injury and could shorten surgery. However, its effectiveness has never been directly compared with the current gold-standard graft in a controlled clinical trial-providing the rationale for the present study.

Our study will test a new, ready-to-use collagen membrane called Star Matrix as an alternative for the conventional surgery that takes a strip of a patient's own tissue from the roof of the mouth (an autogenous gingival graft) to augment thin or missing gum. We will enroll twelve adult patients who need gum thickening on both sides of their lower jaw; each person will receive Star Matrix on one side and their own tissue on the opposite side, so every patient acts as their own control. Our goals are:

  1. Primary aim - gingival augmentation

    o Find out whether Star Matrix can widen the firm, protective gum (keratinized gum tissue) around teeth by at least the same amount as the patient-derived tissue six months after surgery.

  2. Comfort aim - early healing experience

    o Compare how much pain patients feel during the first week after each procedure, using a simple daily pain scale (0 = no pain, 10 = worst possible pain).

  3. Appearance aim - color and texture match

    o Judge how well the new gum created by each method blends in with nearby gum (color and surface feel) six months after surgery, using standardized photographs and a validated rating sheet.

  4. Efficiency aim - surgery time

    o Record and compare the time the periodontist needs to complete each type of procedure, to see if Star Matrix shortens time in the chair for patients and clinicians.

  5. Exploratory aim - tissue quality (optional) o In volunteers who give permission, collect a very small gum sample (2x2 mm2) at six months to look under the microscope and describe how Star Matrix has been replaced by the patient's own tissue.

These aims will show whether Star Matrix can provide equal or better gum growth with less pain and surgical time, potentially giving patients a single-site, more comfortable alternative to current care.

02

Conditions studied

  • Lack of Keratinized Gingiva
  • Mucogingival Deformity - Insufficient Keratinized Tissue

Keywords

  • mucogingival deformity
03

In context

Lead sponsor

Harvard Medical School (HMS and HSDM) is the lead sponsor of 53 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults 20 - 80 years old who need gingival augmentation on both sides of the lower jaw.
  • Able and willing to sign the consent form, follow study instructions and return for all visits
  • Generally healthy (no significant illnesses or medicines that could interfere with healing).
  • Demonstrates good daily oral hygiene (low plaque levels at baseline).

Exclusion criteria

Exclusion Criteria:

  • Does not meet any of the inclusion points or is unlikely to follow the schedule
  • Previous gingival graft at the study site that failed
  • Needs a root-coverage (recession-repair) procedure instead of simple width augmentation
  • Active, untreated gum disease, cavities, infection, or chronic inflammation near the study teeth
  • Used cigarettes, e-cigarettes, or other nicotine products within 3 weeks
  • Insulin-dependent diabetes or hemoglobin A1c > 6.5 %
  • Cancer (other than minor skin cancers or in-situ cervical cancer) within the past 5 years
  • Currently pregnant or breastfeeding
  • Taking (or soon to begin) drugs that change bone turnover (e.g., bisphosphonates, steroids)
  • Diseases that disturb bone metabolism (except common osteoporosis)
  • Auto-immune disease or known allergy to porcine collagen or study materials
  • Active infection at the planned graft site
  • Current use of systemic blood thinners (anticoagulants or antiplatelet agents; e.g., warfarin, heparin/LMWH, DOACs such as apixaban/rivaroxaban/dabigatran/edoxaban, or P2Y12 inhibitors such as clopidogrel/prasugrel/ticagrelor)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Autogenous gingival graft/ free gingival graft (FGG)

    the area will receive conventional gingival augmentation procedure with use of autogenous gingival graft/ free gingival graft (FGG)

    Other: Autogenous gingival graft

  • Experimental
    Starmatrix collagen membrane

    the area will receive conventional gingival augmentation procedure with use of Starmatrix collagen membrane

    Device: Starmatrix collagen membrane

Interventions

  • DeviceStarmatrix collagen membrane

    Our study will test a new, ready-to-use collagen membrane called Star Matrix as an alternative for the conventional surgery that takes a strip of a patient's own tissue from the roof of the mouth (an autogenous gingival graft) to augment thin or missing gum.

  • OtherAutogenous gingival graft

    gingival insufficiency will be treated with autogenous gingival graft

06

What researchers measure

Primary outcomes

  1. increase in keratinized-tissue width

    pre- and post-operative width of keratinized gingiva in the treated area will be measured and compared

    Time frame: 6 months

Secondary outcomes

  1. pain level

    p't will be given a scale of 0-10 for pain experienced during the first week after procedure

    Time frame: 7 days

  2. color matching

    standardized photographs will be used to evaluate gingival color

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Harvard Dental Center
    Boston, Massachusetts 02115, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07440303
Lead sponsor
Harvard Medical School (HMS and HSDM)
Responsible party
David Kim (Associate Professor, Harvard Medical School (HMS and HSDM)) — Principal investigator
First posted
Feb 27, 2026
Start date
Nov 6, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

David Kim, DDS, DMSc
Contact
dkim@hsdm.harvard.edu
(617) 432-1434

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion